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Skin autofluorescence, a non-invasive 
biomarker for advanced glycation end products, 
is associated with the metabolic syndrome 
and its individual components
Robert P. van Waateringe1*, Sandra N. Slagter1, Andre P. van Beek1, Melanie M. van der Klauw1, 
Jana V. van Vliet‑Ostaptchouk1, Reindert Graaff1, Andrew D. Paterson2, Helen L. Lutgers3 
and Bruce H. R. Wolffenbuttel1
Abstract 
Background: The metabolic syndrome (MetS) comprises several cardiometabolic risk factors associated with 
increased risk for both type 2 diabetes and cardiovascular disease. Skin autofluorescence (SAF), a non‑invasive bio‑
marker of advanced glycation end products accumulation, is associated with cardiovascular complications in subjects 
with diabetes. The aim of the present study was to examine the association between SAF and the presence of MetS as 
well as its individual components in a general population.
Methods: For this cross‑sectional analysis, we included 78,671 non‑diabetic subjects between 18 and 80 years of 
age who participated in the LifeLines Cohort Study and had SAF measurement obtained non‑invasively using the 
AGE Reader. MetS was defined according to the revised NCEP ATP III criteria. Students unpaired t test was used to test 
differences between groups. Both logistic and linear regression analyses were performed in order to test associations 
between the individual MetS components and SAF.
Results: Subjects with MetS had higher SAF (2.07 ± 0.45 arbitrary units, AU) compared to individuals without 
MetS (1.89 ± 0.42 AU) (p < 0.001). There was a positive association between the number of MetS components and 
higher SAF Z‑scores (p < 0.001). Individuals in the highest SAF tertile had a higher presence of MetS (OR 2.61; 95% CI 
2.48–2.75) and some of the individual components compared to subjects in the lowest SAF tertile. After correction for 
age, gender, creatinine clearance, HbA1c and smoking status, only elevated blood pressure and low HDL cholesterol 
remained significantly associated with higher SAF (p = 0.002 and p = 0.001 respectively).
Conclusion: Skin autofluorescence was associated with the presence of MetS and some of its individual compo‑
nents. In addition, increasing SAF Z‑scores were observed with a higher number of MetS components. Prospective 
studies are needed to establish whether SAF can be used as an (additional) screening tool to predict both cardiovas‑
cular disease and type 2 diabetes in high‑risk populations.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Advanced glycation end products (AGEs) comprise a 
group of largely irreversibly glycated proteins, lipids and 
nucleic acids which represent chronic exposure to hyper-
glycaemia and oxidative stress [1, 2]. AGEs are formed via 
several pathways, usually the Maillard reaction between 
carbonyl groups of reducing sugars and free amino 
groups from proteins. AGEs accumulate in the skin as a 
result of ageing [3, 4]. The formation and accumulation 
may be increased as a result of both endogenous and 
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impaired renal excretion in subjects with kidney failure, 
as well as dietary intake and tobacco smoking [5–8].
Since the past decade, it has become possible to esti-
mate tissue AGE accumulation non-invasively by meas-
uring autofluorescence of the skin (SAF) [9]. In our 
previous study we showed that SAF was associated with 
several clinical and lifestyle parameters [10]. SAF has 
previously been validated against tissue AGE measure-
ments and reference values against age were obtained 
[11, 12]. SAF was reported to be elevated in subjects with 
type 1 and 2 diabetes [9, 13]. Moreover, SAF has been 
shown to be a strong predictor of long-term cardiovas-
cular complications and mortality in both type 1 and type 
2 diabetes and end-stage renal failure [14–18]. In addi-
tion, recent studies have shown higher SAF levels to be 
associated with coronary artery disease, peripheral artery 
disease and (sub)clinical atherosclerosis independent of 
diabetes [19–21].
The metabolic syndrome (MetS) is a cluster of cardio-
metabolic abnormalities associated with increased risk 
for cardiovascular disease (CVD) and type 2 diabetes 
mellitus [22, 23]. The MetS is a worldwide problem which 
prevalence increases worldwide, particularly due to the 
growing epidemic of obesity [24–26]. Glycation is known 
to play an essential role in the mechanism that leads to 
the formation of AGEs [6].
It has been shown that AGEs increase inflammation 
and oxidative stress hereby promoting insulin resistance. 
On the other hand, a low AGEs diet improves insulin 
sensitivity [27, 28].
However, the association of the other cardiometabolic 
components with SAF has not been assessed in detail. As 
SAF measurement might be used as a future screening 
tool in high-risk populations, such as the MetS, to refine 
estimation of risk of future cardiovascular events or 
development of type 2 diabetes, knowledge of potential 
associations with SAF is important. Therefore, the aim of 
this cross-sectional study was to assess SAF in subjects 
with MetS. We examined the association between the 




Subjects included were participants from the LifeLines 
Cohort Study [29], a large population-based cohort 
study in the northern region of the Netherlands exam-
ining the interaction between genetic and environ-
mental factors associated with chronic diseases and 
healthy ageing. Between 2006 and 2013, individuals 
from the three northern provinces of the Netherlands 
were invited to participate in the study. At baseline, 
both physical examination and extensive question-
naires were collected from more than 167,000 par-
ticipants [30]. All participants have provided written 
informed consent before participating in the study. The 
study has been approved by the Medical Ethics Review 
Committee of the University Medical Center Gron-
ingen. For the present study, we included subjects of 
Western European descent between 18 and 80 years of 
age having a SAF measurement available (n =  82,515). 
We excluded subjects with either missing data for 
MetS status (n = 1221) and those with a serum creati-
nine >140 µmol/L (n = 75), as severely reduced kidney 
function itself increases AGE levels. Furthermore, sub-
jects with missing data for diabetes status (n = 86) were 
excluded, as were those with type 1 diabetes (n = 177), 
type 2 diabetes (n = 2157) or previous gestational dia-
betes (n = 128) leaving 78,671 non-diabetic individuals 
for analyses.
Clinical and lifestyle data
The following clinical data were used: age, gender, body 
mass index (BMI), waist circumference, systolic and dias-
tolic blood pressure, serum lipids, fasting plasma glucose, 
HbA1c, creatinine clearance, use of medication, and self-
reported history of CVD (myocardial infarction and cer-
ebrovascular accident). Information regarding smoking 
behaviour was collected by extensive questionnaires, as 
described earlier [10]. Pack-years of smoking were cal-
culated as the number of cigarette packages smoked per 
day multiplied by the number of years an individual had 
smoked. Data regarding coffee consumption (cups of cof-
fee per day) were obtained by questionnaire. We were not 
able to distinguish between caffeinated and decaffeinated 
coffee consumption.
Physical measurements
Weight was measured to the nearest 0.1 kg and height 
and waist circumference to the nearest 0.5  cm by 
trained technicians using calibrated measuring equip-
ment, with participants wearing light clothing and no 
shoes. Waist circumference was measured with a tape 
around the body between the lower rib margin and 
the iliac crest. BMI was calculated as weight divided 
by height squared (kg/m2). Systolic and diastolic blood 
pressure were measured every minute during 10 min in 
the supine position using an automated Dinamap Moni-
tor (GE Healthcare, Freiburg, Germany). The average of 
the last three readings was recorded. SAF was assessed 
as the mean of three consecutive measurements using 
the AGE Reader (DiagnOptics Technologies BV, Gron-
ingen, the Netherlands) in all participants, as described 
previously [9–11].
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Biochemical measures
Blood samples were taken in the fasting state between 
8.00 and 10.00 a.m. and transported to the LifeLines lab-
oratory facility at room temperature or at 4 °C, depend-
ing on the sample requirements. On the day of collection, 
HbA1c (EDTA-anticoagulated) was analyzed using a 
NGSP-certified turbidimetric inhibition immunoas-
say on a Cobas Integra 800 CTS analyzer (Roche Diag-
nostics Nederland BV, Almere, the Netherlands). Serum 
creatinine was measured on a Roche Modular P chem-
istry analyzer (Roche, Basel Switzerland), and creatinine 
clearance was calculated with the chronic kidney disease 
epidemiology collaboration (CKD-EPI) formula [31]. 
Total and high density lipoprotein (HDL) cholesterol 
were measured using an enzymatic colorimetric method, 
triglycerides using a colorimetric UV method, and low 
density lipoprotein (LDL) cholesterol using an enzy-
matic method, on a Roche Modular P chemistry analyzer 
(Roche, Basel, Switzerland). Fasting blood glucose was 
measured using a hexokinase method.
Definition of the metabolic syndrome
Diagnosis of MetS was established if a subject satisfied 
at least three out of five criteria according to the revised 
National Cholesterol Education Programs Adults Treat-
ment Panel III (NCEP ATPIII criteria) [22]: (1) systolic 
blood pressure ≥130 mmHg and/or diastolic blood pres-
sure  ≥85  mmHg and/or use of antihypertensive medi-
cation; (2) HDL cholesterol levels <1.03 mmol/L in men 
and <1.30 mmol/L in women and/or use of lipid-lowering 
medication influencing HDL levels; (3) triglyceride lev-
els  ≥1.70  mmol/L and/or use of triglyceride-lowering 
medication; (4) waist circumference  ≥102  cm in men 
and ≥88 cm in women; (5) fasting glucose level between 
5.6 and 7.0  mmol/L. As mentioned earlier, people with 
diabetes were excluded from analysis to reflect ‘true’ 
MetS.
Calculations and statistical analyses
Data are shown as mean  ±  standard deviation (SD) or 
median and interquartile range (IQR) in case of non-
normally distributed data. Student’s unpaired t test, 
Analysis of Variance (ANOVA) or Chi Square test were 
performed to compare groups. Age-adjusted SAF levels 
(Z-scores) were calculated based on the total popula-
tion (separated for males and females) as SAF and MetS 
are strongly affect by ageing [10, 32]. Next, we classi-
fied individuals into tertiles of their age-adjusted SAF 
Z-scores, in men: lowest SAF Z  ≤  −0.59, intermedi-
ate SAF −0.60  <  Z  <  0.49 and highest SAF Z  ≥  0.50; 
in women: lowest SAF Z  ≤  −0.72, intermediate SAF 
−0.73  <  Z  <  0.33 and highest SAF Z  ≥  0.34. Logistic 
regression analysis was performed to assess whether 
either of the SAF groups (low SAF was set as a refer-
ence) were associated with the presence of MetS and its 
components. Model 1 shows the unadjusted association 
between tertiles of SAF Z-scores and MetS as well as its 
individual components. In model 2, we adjusted for gen-
der and BMI. In model 3, we additionally adjusted for cre-
atinine clearance, HbA1c, current smoking, pack-years 
and CVD history. Linear regression analysis was per-
formed to examine the association between each of the 
individual MetS components and SAF among the popu-
lation with MetS. In the multivariate models, we adjusted 
for determinants of SAF reported in our previous study, 
including age, gender, BMI, creatinine clearance, HbA1c, 
smoking status, packyears, and CVD history [10]. SPSS 
(version 22, IBM, Armonk, NY, USA) was used for statis-




Table  1 shows the clinical characteristics of the study 
population stratified for gender and MetS status. The 
overall prevalence of MetS was 19% in men and 12% in 
women.
In both genders, individuals with MetS were older than 
subjects without MetS and had a significantly higher BMI 
and waist circumference (all p < 0.001). Both in men and 
women, the prevalence of MI (3.5% in men and 1.0% in 
women) and CVA (1.1% in men and 1.2% in women) was 
higher among individuals with MetS compared to sub-
jects without MetS (p  <  0.001). The percentage of cur-
rent smokers as well as the number of pack-years smoked 
(p  <  0.001) were higher in the participants with MetS. 
In addition, both men and women with MetS reported 
higher consumption of coffee compared to individu-
als without MetS (p < 0.001). Mean SAF levels were sig-
nificantly higher among both male and female subjects 
with MetS compared to individuals without MetS (men: 
2.07  ±  0.44 AU vs 1.94  ±  0.43 AU, p  <  0.001; women: 
2.07 ± 0.45 AU vs 1.86 ± 0.42 AU, p < 0.001). In subjects 
with MetS, mean SAF levels were not different between 
men and women (2.07  ±  0.44 AU vs 2.07  ±  0.45 AU, 
p =  0.715). However, among individuals without MetS, 
men had significantly higher SAF levels than women 
(1.94 ± 0.43 AU vs 1.86 ± 0.42 AU, p < 0.001) (data not 
shown). Furthermore, mean SAF was 2.33  ±  0.50 AU 
in subjects with a history of MI and 1.91 ±  0.43 AU in 
subjects without a history of MI (p < 0.001). Mean SAF 
was 2.22  ±  0.50 AU in subjects with a history of CVA 
and 1.91 ± 0.43 AU in subjects without a history of CVA 
(p < 0.001) (data not shown). Finally, within obese indi-
viduals, subjects with MetS had a higher SAF than indi-
viduals without MetS (2.11 ± 0.47 AU vs 1.94 v 0.41 AU, 
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p  <  0.001). However, within the population with MetS, 
there was no significant difference in SAF between obese 
and non-obese individuals (2.07 ± 0.45 AU vs 2.06 v 0.45 
AU, p = 0.46) (data not shown).
The association between SAF and the number of MetS 
components
In both men and women, we observed a gradual rise 
in age-adjusted SAF Z-scores with higher number 
of individuals MetS components. Compared to men 
without any MetS components, SAF Z-scores were 
significantly higher among subjects with ≥1 MetS com-
ponent (p < 0.001). Men with ≥2 MetS components had 
significantly higher SAF Z-scores compared to men hav-
ing only one MetS component (p  <  0.001). No signifi-
cant differences in SAF Z-scores were observed between 
men with two vs three MetS components as well as men 
with four vs five MetS components. Among women, SAF 
Z-scores were significantly higher among those with ≥1 
MetS component compared to women without any MetS 
components (p < 0.001). Women with three, four or five 
MetS components had significantly higher SAF Z-scores 
Table 1 Clinical characteristics of the study population stratified by MetS status and gender
Data are presented as mean ± standard deviation, or median (interquartile range) and number (%)
AU arbitrary units, BP blood pressure, CVA cerebrovascular accident, GFR Glomerular Filtration Rate, HDL high density lipoprotein, LDL low density lipoprotein, MetS 
metabolic syndrome, Mi myocardial infarction, SAF skin autofluorescence, TG triglycerides
* p value <0.001
a Creatinine clearance (Cockcroft-Gault formula), b Creatinine clearance (CKD EPI)
Characteristic Men (n = 32,601) Women (n = 46,070)
MetS Without MetS MetS Without MetS
n (%) 6220 (19) 26,381 (81) 5367 (12) 40,703 (88)
Age (years) 49 ± 11* 44 ± 13 50 ± 12* 44 ± 12
Body mass index (kg/m2) 29.8 ± 3.6* 25.5 ± 3.1 30.6 ± 5.1* 25.1 ± 4.1
Waist circumference (cm) 106 ± 9* 93 ± 9 100 ± 11* 85 ± 11
Systolic blood pressure (mmHg) 141 ± 14* 129 ± 14 138 ± 16* 121 ± 15
Diastolic blood pressure (mmHg) 82 ± 9* 76 ± 9 79 ± 9* 72 ± 9
Total cholesterol (mmol/L) 5.4 ± 1.1* 5.1 ± 1.0 5.4 ± 1.1* 5.0 ± 1.0
HDL cholesterol (mmol/L) 1.04 ± 0.23* 1.37 ± 0.30 1.24 ± 0.30* 1.65 ± 0.38
LDL cholesterol (mmol/L) 3.56 ± 0.93* 3.35 ± 0.89 3.57 ± 0.95* 3.05 ± 0.88
Triglycerides (mmol/L) 2.03 (1.60–2.73)* 1.04 (0.77–1.40) 1.72 (1.18–2.14)* 0.83 (0.64–1.11)
Creatinine clearance (mL/min)a 137 ± 36* 124 ± 28 125 ± 39* 111 ± 29
Creatinine clearance (mL/min)b 130 ± 18* 128 ± 16 135 ± 21 134 ± 18
Fasting plasma glucose (mmol/L) 5.45 ± 0.55* 4.98 ± 0.43 5.33 ± 0.61* 4.75 ± 0.42
HbA1c (%) 5.7 ± 0.3* 5.5 ± 0.3 5.7 ± 0.4* 5.5 ± 0.3
HbA1c (mmol/mol) 38.5 ± 3.8 36.7 ± 3.2 39.3 ± 3.9 36.5 ± 3.2
Statin use, n (%) 783 (13)* 1260 (5) 554 (10)* 1029 (3)
TG‑lowering medication, n (%) 44 (1)* 9 (0.01) 16 (0.3)* 3 (0.01)
BP‑lowering medication, n (%) 1445 (23)* 2008 (8) 1919 (36)* 3099 (8)
MI, n (%) 214 (3.5)* 289 (1.1) 56 (1.0)* 94 (0.2)
CVA, n (%) 70 (1.1)* 188 (0.7) 66 (1.2)* 203 (0.5)
Coffee consumption (cups per day) 4.7 (2.8–5.6)* 3.7 (2.8–5.6) 3.3 (1.9–4.7)* 2.8 (1.3–4.7)
Smoking status, n (%)
 Non‑smokers 2117 (34)* 12,259 (47) 2203 (41)* 19,836 (49)
 Ex‑smokers 2425 (39) 8271 (32) 1899 (36) 12,847 (32)
 Current smokers 1629 (27) 5677 (21) 1228 (23) 7698 (19)
Pack‑years
 Ex‑smokers 12.8 (6.5–21.9)* 8.2 (3.8–15.0) 7.8 (3.5–15.3)* 5.2 (2.2–10.4)
 Current‑smokers 18.0 (10.7–27.0)* 12.9 (6.4–21.5) 16.9 (9.6–26.3)* 11.2 (5.4–18.8)
SAF (AU) 2.07 ± 0.44* 1.94 ± 0.43 2.07 ± 0.45* 1.86 ± 0.42
SAF Z‑score 0.21 ± 0.02* 0.04 ± 0.01 0.19 ± 0.02* −0.10 ± 0.01
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compared to women with only one MetS component 
(p  <  0.001). No differences in SAF Z-scores were found 
for women with two vs one MetS components as well as 
three vs two MetS components. Furthermore, women 
with either four or five MetS components had signifi-
cantly higher SAF Z-scores than women with two MetS 
components or three MetS components (p  <  0.001). In 
men, SAF Z-scores tended to be higher in those with one, 
two and three MetS components while in women SAF 
Z-scores were higher in three, four or five MetS compo-
nents compared to men (Fig. 1).
SAF and the prevalence of the individual MetS 
components
Figure  2 shows the prevalence of the individual MetS 
components for both men and women in the total study 
population according to tertiles of age-adjusted SAF 
Z-scores. Among men, individuals in the highest SAF 
Fig. 1 Age‑adjusted SAF Z‑scores increase with a higher number of MetS components. Bars reflect mean SAF Z‑scores ± standard error. Men: no 
MetS component (n = 8999), one MetS component (n = 10,535), two MetS components (n = 6847), three MetS components (3955), four MetS 
components (n = 1821), five MetS components (n = 445). Women: no MetS component (n = 17,062), one MetS component (n = 14,423), two 
MetS components (n = 928), three MetS components (n = 3725), four MetS components (n = 1365), five MetS components (n = 277). SAF skin 
autofluorescence, MetS metabolic syndrome
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Fig. 2 Prevalence of the individual MetS components according to tertiles of age‑adjusted SAF Z‑scores. Bars show percentage of the metabolic 
syndrome components. Lowest, intermediate and highest group are based on tertiles of age‑adjusted SAF Z‑scores. SAF skin autofluorescence
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groups had a higher prevalence of elevated blood pres-
sure (58%) compared to subjects in the middle (52%) and 
lowest SAF group (54%).
We observed the same trend for enlarged waist circum-
ference, impaired fasting glucose, elevated triglycerides 
and low HDL cholesterol (all p < 0.001).
In contrast to men, the most frequent MetS component 
in women was enlarged waist circumference (high SAF 
48%, intermediate SAF 41% and lowest SAF 41%). There 
was a clear and significant trend among women within the 
highest SAF group, to be associated with higher prevalence 
of blood pressure, elevated triglycerides, lower HDL cho-
lesterol levels and impaired fasting glucose (all p < 0.001).
Logistic regression analysis for the presence of MetS and it 
components across SAF tertiles
Table 2 shows the results of the logistic regression analy-
ses describing the association between SAF tertiles and 
the presence of MetS in the total population. Compared 
to the low SAF group which was set as a reference, high 
SAF was significantly associated with a higher pres-
ence of MetS (odds ratio (OR) 2.61; 95% CI 2.48–2.75). 
After adjusting for age, gender, BMI, creatinine clear-
ance, HbA1c, smoking status, packyears, CVD history, 
high SAF (OR 1.24; 95% CI 1.13–1.37) and intermediate 
SAF (OR 1.11; 95% CI 1.01–1.22) remained significantly 
associated with the presence of MetS (Table 2, model 3). 
Table 2 Unadjusted and adjusted odds ratios for metabolic syndrome and its components associated with tertiles of SAF 
(total population)
Data are presented as odds ratios (95% confidence interval) per arbitrary unit (AU). SAF groups were based on tertiles of age-adjusted SAF Z-scores. Model 
1 = unadjusted; model 2 = adjusted for age, gender, BMI; model 3 = adjusted for age, gender, BMI, HbA1c, creatinine clearance, current smoking, pack-years, MI and 
CVA
Significant associations are shown in italic
BMI body mass index, CVA cerebrovascular accident, HDL high density lipoprotein, MI myocardial infarction, OR odds ratio, SAF skin autofluorescence
Metabolic syndrome Model 1 Model 2 Model 3
OR p value OR p value OR p value
SAF (continuous) 2.37 (2.27−2.48) <0.0001 1.36 (1.28–1.44) <0.0001 1.17 (1.08–1.26) <0.0001
 Low SAF Ref. Ref. Ref.
 Intermediate SAF 1.71 (1.62–1.81) <0.0001 1.13 (1.06–1.21) <0.0001 1.11 (1.01–1.22) 0.031
 High SAF 2.61 (2.48–2.75) <0.0001 1.38 (1.29–1.48) <0.0001 1.24 (1.13–1.37) <0.0001
Elevated blood pressure
 SAF (continuous) 3.03 (2.92–3.14) <0.0001 1.25 (1.20–1.31) <0.0001 1.21 (1.14–1.29) <0.0001
  Low SAF Ref. Ref. Ref.
  Intermediate SAF 1.71 (1.65–1.77) <0.0001 1.06 (1.02–1.11) 0.005 1.04 (0.98–1.11) 0.220
  High SAF 2.93 (2.82–3.03) <0.0001 1.18 (1.12–1.24) <0.0001 1.16 (1.08–1.24) <0.0001
Impaired fasting glucose
 SAF (continuous) 2.59 (2.47–2.72) <0.0001 1.17 (1.10–1.25) <0.0001 1.09 (1.00–1.19) 0.049
  Low SAF Ref. Ref. Ref.
  Intermediate SAF 1.90 (1.78–2.03) <0.0001 1.09 (1.01–1.17) 0.026 1.08 (0.97–1.20) 0.185
  High SAF 3.16 (2.97–3.37) <0.0001 1.34 (1.24–1.45) <0.0001 1.27 (1.14–1.42) <0.0001
Low HDL cholesterol
 SAF (continuous) 1.08 (1.03–1.12) 0.001 1.46 (1.39–1.54) <0.0001 1.27 (1.19–1.36) <0.0001
  Low SAF Ref. Ref. Ref.
  Intermediate SAF 0.96 (0.92–1.01) 0.082 1.08 (1.02–1.13) 0.004 1.02 (0.94–1.10) 0.663
  High SAF 1.01 (0.96–1.05) 0.786 1.27 (1.20–1.34) <0.0001 1.13 (1.04–1.22) 0.003
Elevated triglycerides
 SAF (continuous) 1.78 (1.70–1.85) <0.0001 1.29 (1.22–1.37) <0.0001 1.08 (1.00–1.16) 0.029
  Low SAF Ref. Ref. Ref.
  Intermediate SAF 1.49 (1.41–1.57) <0.0001 1.12 (1.05–1.18) <0.0001 1.04 (0.95–1.13) 0.426
  High SAF 1.89 (1.80–1.98) <0.0001 1.34 (1.25–1.42) <0.0001 1.17 (1.07–1.28) 0.001
Enlarged waist circumference
 SAF (continuous) 1.89 (1.82–1.95) <0.0001 1.31 (1.23–1.39) <0.0001 1.32 (1.21–1.44) <0.0001
  Low SAF Ref. Ref. Ref.
  Intermediate SAF 1.45 (1.40–1.50) <0.0001 1.11 (1.05–1.18) 0.001 1.14 (1.04–1.25) 0.004
  High SAF 1.93 (1.86–2.00) <0.0001 1.26 (1.18–1.35) <0.0001 1.32 (1.20–1.46) <0.0001
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Considering the individual MetS components, high SAF 
(OR 3.16; 95% CI 2.97–3.37 and intermediate SAF (OR 
1.90; 95% CI 1.78–2.03) were significantly associated 
with the presence of impaired fasting glucose, although 
the OR attenuated after adjusting for several covariables 
(Table 2, models 1, 2 and 3). We also found high SAF (OR 
2.93; 95% CI 2.82–3.03) and intermediate SAF (OR 1.71; 
95% CI 1.65–1.77) to be associated with the presence 
of elevated blood pressure (Table  2, model 1). Finally, 
high SAF (OR 1.93; 95% CI 1.86–2.00) and intermedi-
ate SAF (OR 1.45; 95% CI 1.40–1.50) were also associ-
ated with the presence of enlarged waist circumference, 
which remained significant after adjusting for covariables 
(Table 2, models 1, 2 and 3).
Associations for SAF in the metabolic syndrome 
population
The univariate associations between the individual MetS 
components and SAF levels in the MetS population are 
shown in Table  3. In subjects with MetS, the impaired 
fasting glucose and elevated blood pressure compo-
nents gave the strongest increase in SAF. Subjects with 
MetS having the impaired fasting glucose component 
had a 0.12 AU higher SAF compared to subjects with-
out this particular component. A similar association was 
observed for individuals with MetS having the elevated 
blood pressure who had a 0.11 AU higher SAF than those 
without elevated blood pressure. Multivariate analyses 
showed that after adjusting for several determinants of 
SAF, elevated blood pressure (0.05 AU) and low HDL 
cholesterol (0.04 AU) were significantly associated with 
higher SAF. Impaired fasting glucose, elevated triglyc-
erides and enlarged waist circumference were not sig-
nificantly associated with SAF. Regarding the clinical and 
lifestyle factors, age, HbA1c, current smoking, packyears 
and a history of CVD were all significantly associated 
with higher SAF whereas a higher creatinine clearance 
was associated with lower SAF.
Discussion
In the present study, we have demonstrated that SAF lev-
els were higher in both male and female participants with 
MetS compared to those without MetS. Furthermore, 
SAF was significantly and independently associated with 
the presence of MetS and some of its individual com-
ponents, particularly elevated blood pressure, impaired 
fasting glucose and enlarged waist circumference.
One of the main findings of the present study was that 
we observed significantly higher SAF levels in subjects 
with MetS compared to individuals without MetS, which 
is in line with a study by Den Engelsen et al. [33]. These 
authors observed higher SAF levels in obese subjects 
with MetS compared to those without MetS. The latter 
group may be considered as “healthy obese”, which is also 
reflected by their SAF level. Additional analyses on our 
data showed a similar pattern (data not shown). In our 
study, 45% of men and 51% of women with MetS were 
obese, as defined by a BMI above 30  kg/m2. However, 
within the population with MetS, we did not observe a 
statistically significant difference in SAF between obese 
and non-obese individuals. Within the same population, 
subjects with an enlarged waist circumference had higher 
SAF than subjects without an enlarged waist circumfer-
ence. These findings imply that not general obesity but 
an enlarged waist circumference, or visceral obesity has 
more impact on SAF within individuals with MetS.
Next, our results may not be compared directly to those 
from Monami et al. [34] who have also shown that SAF 
levels are elevated among diabetic individuals with MetS. 
Mean SAF was higher than in our study as their cohort 
primarily consisted of type 2 diabetic individuals with 
a mean diabetes duration of 12  years. Individuals with 
type 2 diabetes have in general higher SAF than subjects 
Table 3 Associations for skin autofluorescence in the met-
abolic syndrome population
Data are shown as coefficient B (standard error) per arbitrary unit (AU). The 
individual MetS components were included into the model as categorical 
variables (yes/no) while the other variables were continuous variables
Significant associations are shown in italic
CVA cerebrovascular accident, HDL high density lipoprotein, MI myocardial 
infarction
a Current smoking vs non- and former smoking
Coefficient B SE p value
Univariate model
 Elevated blood pressure 0.113 0.012 <0.0001
 Low HDL cholesterol −0.094 0.009 <0.001
 Elevated triglycerides 0.029 0.009 0.001
 Impaired fasting glucose 0.124 0.008 <0.0001
 Enlarged waist circumference 0.038 0.011 0.001
Multivariate model
 Elevated blood pressure 0.044 0.015 0.003
 Low HDL cholesterol 0.036 0.012 0.002
 Elevated triglycerides −0.001 0.011 0.920
 Impaired fasting glucose 0.008 0.012 0.502
 Enlarged waist circumference 0.016 0.014 0.269
  Age 0.019 0.001 1.3 × 10−159
  Male gender −0.016 0.011 0.272
  Creatinine clearance (mL/min) 0.001 0.0002 0.014
  HbA1c (%) 0.055 0.016 2.3 × 10−4
  Coffee consumption (cups/
day)
0.024 0.002 6.6 × 10−29
  Current  smokinga 0.116 0.011 1.1 × 10−23
  Pack‑years 0.004 0.0003 5.6 × 10−31
  MI 0.062 0.029 0.033
  CVA 0.026 0.043 0.562
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without diabetes [9]. Furthermore, subjects in their study 
were older and had a higher prevalence of CVD, both are 
associated with higher SAF [11, 14].
In addition to the observation of higher SAF levels in 
subjects with MetS, we also found that a higher num-
ber of individual MetS components coincides with even 
higher SAF Z-scores. A previous study has already shown 
that a higher number of MetS components was associ-
ated with higher serum AGEs levels [35]. Clinical studies 
have demonstrated that a higher number of MetS com-
ponents is associated with both incident CVD and type 
2 diabetes [36–38]. Klein et  al. showed that individuals 
with one MetS components had 2.5% risk of incident 
CVD in the next 5  years whereas subjects with four or 
more MetS components had an almost 15% risk. The 
5-years risk for type 2 diabetes increased from 1.1% (one 
MetS component) to 17.9% (≥four MetS components) 
[36]. An 11-year follow-up study demonstrated an almost 
linear relationship between the number of individual 
MetS components and the risk of coronary heart disease 
in subjects without a history of CVD or type 2 diabetes 
[38]. Therefore, we suggest that an increase in SAF may 
reflect an even higher risk of type 2 diabetes and CVD.
It has been reported that the prevalence of both MetS 
and its components differ between men and women 
[39]. In men, we observed that elevated blood pressure 
was the most prevalent MetS component. Moreover, we 
found that subjects in the highest SAF group had a higher 
prevalence of elevated blood pressure compared to indi-
viduals in the intermediate or lowest SAF group. A few 
studies have described the association between SAF and 
elevated blood pressure, but the results are contradictory. 
For example, in renal transplant recipients, systolic blood 
pressure was positively associated with SAF [40] whereas 
neither systolic nor diastolic blood pressure was related 
to SAF in a recent Japanese study among type 2 dia-
betic individuals [41]. A recent study by Botros et al. [42] 
showed that both systolic and diastolic blood pressure 
were significantly associated with SAF. They showed that 
individuals with elevated blood pressure had a higher 
odds for having a SAF level > median, compared to sub-
jects without elevated blood pressure. Elevated blood 
pressure may well be a consequence of increased AGE 
accumulation. A recent study demonstrated that carotid-
femoral pulse-wave velocity and central pulse pressure 
were independently associated with plasma AGEs [43]. 
Several AGEs are able to form crosslinks within collagen 
in the vascular wall, which may result in impaired vas-
cular elasticity and increased arterial stiffness, causing 
blood pressure to rise [44, 45]. Our data together with 
previous studies suggest that AGE accumulation may 
indeed be involved in the underlying pathophysiology of 
elevated blood pressure.
In contrast to men among we found elevated blood 
pressure to be the most prevalent component, we 
observed that enlarged waist circumference was the 
most prevalent MetS component among women. Indi-
viduals with high SAF levels had a higher presence of 
enlarged waist circumference compared to subjects with 
intermediate or low SAF levels. However, in the mul-
tivariable analyses, enlarged waist circumference was 
not significantly associated with SAF. The correlation 
between waist circumference or BMI and higher SAF 
levels has been demonstrated among subjects with type 
2 diabetes [34]. Recently, it has been shown that SAF lev-
els were elevated among individuals with central obesity 
compared to lean subjects [33]. Interestingly, Angoorani 
et  al. [46] have demonstrated that dietary consump-
tion of AGEs is associated with MetS, and in particular 
abdominal obesity. Furthermore, it was observed that 
an increased consumption of food AGEs was associated 
with an even higher risk of (abdominal) obesity. They 
reported that individuals with a high AGEs consumption 
had a higher fat intake, and indeed it is known that fat 
contains a significant amount of dietary AGEs per gram 
of weight [47]. Another possible mechanism that has 
been reported to increase AGEs accumulation in obese 
individuals is oxidative stress [48, 49]. Autoxidation of 
lipoproteins result in the formation of advanced lipoxida-
tion end products formation (ALEs) such as carboxym-
ethyllysine (CML) [1].
Next, we have shown that higher SAF is significantly 
associated with an  increased presence of impaired fast-
ing glucose. After adjusting for HbA1c, impaired fast-
ing glucose was not associated with SAF  probably as 
a consequence of high collinearity. A previous study 
already demonstrated that among subjects with central 
obesity, fasting glucose levels were significantly associ-
ated with higher SAF in univariate regression analy-
ses but not after adjusting for covariables [33]. Another 
recent study reported no significant difference in plasma 
AGEs between women with normal fasting glucose and 
impaired fasting glucose [50]. As we included in our 
study subjects without diabetes only, and glucose levels 
were relatively low (<6.9  mmol/L), this may be the rea-
son why fasting glucose was not associated with SAF. In 
individuals with diabetes, the formation of AGEs is accel-
erated particularly due to (chronic) hyperglycaemia [51]. 
Glucose plays an essential role in the formation of AGEs 
as protein amino groups and lipids are non-enzymatically 
glycated to form stable structures on long-lived tissues 
[4, 52]. A second pathway which leads to the formation 
of AGEs is through autoxidation of glucose by reactive 
oxygen species and through formation of carbonyl com-
pounds [1]. It has been shown that AGEs are involved in 
beta-cell injury, probably caused by inflammation and 
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oxidative stress thought the AGE–RAGE interaction [53]. 
This may be prevented by consumption of a low-AGE 
diet, which has been suggested to improve insulin sensi-
tivity [54, 55].
After adjusting for several determinants, having a low 
HDL cholesterol was significantly associated with higher 
SAF levels but elevated triglycerides was not. Among 
individuals with MetS, HDL was just above the limit in 
men and slightly decreased in women, while statin use 
was 13% in men and 10% in women. Additional analysis 
showed that statin users had significantly higher SAF Z 
scores than those not using statins, also after correcting 
for age. Triglycerides were slightly elevated in women, 
but higher in men. Around 1% of individuals with MetS 
used triglycerides lowering medication. There was no 
significant difference in SAF Z scores between subject 
using triglycerides lowering medication and subjects 
not using this kind of medication. Limited data exist on 
the association between SAF and both HDL cholesterol 
and triglycerides. In subjects with type 2 diabetes, HDL 
cholesterol levels were negatively, and triglycerides were 
positively associated with SAF [14, 34]. Similar associa-
tions have been reported between serum AGEs levels and 
triglycerides and HDL cholesterol levels in diabetes [56]. 
In addition, higher consumption of AGE-rich foods was 
associated with hypertriglyceridemia [46]. HDL choles-
terol has been reported to inhibit oxidative modification 
of LDL cholesterol [57]. A study in 200 type 2 diabetic 
subjects showed that higher anti-oxidative capacity 
of HDL was associated with lower SAF but not plasma 
HDL cholesterol levels itself [58]. Circulating AGEs may 
impair the capacity of HDL to protect against oxidation 
of LDL cholesterol which potentially increases oxida-
tive stress. In turn this might accelerate the formation of 
AGEs [59] and plays a role in atherosclerosis [60].
The strength of this study is its large and well-char-
acterized study population, including high quality data 
on anthropometric and clinical measurements. This 
resulted in a good statistical power and the ability to 
perform stratified analysis. Moreover, this is the largest 
study in subjects without diabetes and impaired renal 
failure showing the association between SAF and several 
cardiometabolic risk factors. A limitation of the study 
includes the cross-sectional design, which does not allow 
us to draw any conclusions about causality in the associa-
tion between SAF levels and the risk of cardiometabolic 
diseases.
Conclusion
The present findings of elevated SAF levels in subjects 
with MetS, the positive association between the num-
ber of individual MetS components and higher SAF lev-
els, as well as the observation that higher SAF levels are 
associated with higher prevalence of the individual com-
ponents, provide further evidence that accumulation 
of AGEs may contribute to the pathophysiology of sev-
eral cardiometabolic risk factors. Prospective studies are 
needed to demonstrate whether SAF measurement can 
be used as an additional non-invasive screening tool to 
detect individuals at high-risk for both CVD and incident 
type 2 diabetes.
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